New research has found that people who take drugs such as Ozempic and Wegovy are more than 50% less likely to develop alcohol use disorder or experience a relapse.

The new generation of weight-loss drugs were initially developed to treat diabetes and work by mimicking a hormone that regulates insulin levels and appetite. When celebrities started shedding pounds with private prescriptions for the diabetes drug Ozempic,

Britain's medical costs regulator on Tuesday recommended Eli Lilly's weight-loss drug Mounjaro for some patients with obesity and suggested not placing a time limit on the medicine's use as it had for rival Novo Nordisk's Wegovy.

The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a research note.

Ozempic and Wegovy appear to improve people's sensitivity to tastes, potentially lowering their desire for sweets, a new study suggests.

Doctors say it will be the 'icing on the cake' if the medicines, which have been shown to cut heart attack and strokes, had a comparable effect on cancer.